期刊
DEPRESSION AND ANXIETY
卷 36, 期 3, 页码 235-243出版社
WILEY
DOI: 10.1002/da.22875
关键词
active placebo; anxious depression; ketamine; major depressive disorder; midazolam; treatment-resistant depression
资金
- National Institute of Mental Health
ObjectiveTo examine the effect of high baseline anxiety on response to ketamine versus midazolam (active placebo) in treatment-resistant depression (TRD). MethodsIn a multisite, double-blind, placebo-controlled trial, 99 subjects with TRD were randomized to one of five arms: a single dose of intravenous ketamine 0.1, 0.2, 0.5, 1.0mg/kg, or midazolam 0.045mg/kg. The primary outcome measure was change in the six-item Hamilton Rating Scale for Depression (HAMD6). A linear mixed effects model was used to examine the effect of anxious depression baseline status (defined by a Hamilton Depression Rating Scale Anxiety-Somatization score 7) on response to ketamine versus midazolam at 1 and 3 days postinfusion. ResultsN=45 subjects had anxious TRD, compared to N=54 subjects without high anxiety at baseline. No statistically significant interaction effect was found between treatment group assignment (combined ketamine treatment groups versus midazolam) and anxious/nonanxious status on HAMD6 score at either days 1 or 3 postinfusion (Day 1: F(1, 84)=0.02, P=0.88; Day 3: F(1, 82)=0.12, P=0.73). ConclusionIn contrast with what is observed with traditional antidepressants, response to ketamine may be similar in both anxious and nonanxious TRD subjects. These pilot results suggest the potential utility of ketamine in the treatment of anxious TRD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据